|D016638||Critical Illness NIH||0.13|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
There is one clinical trial.
A Phase I/II clinical trial for safety and efficacy evaluation of treatment with anti-SARS-CoV-2 equine immunoglobulin (F(ab')2) in hospitalized patients with COVID-19 not requiring of invasive ventilation support.
Description: Viral load reduction evaluated by area under the curve of RT-PCR valuesMeasure: Reduction of viral load evaluated by area under the curve of RT-PCR values Time: Day 0, Day 3, Day 7 and Day 14
Description: number of days between admission and dischargeMeasure: Length of hospital stay Time: For as long as the duration of the hospital stay
Description: Number of patients who progressed to the use of invasive mechanical ventilation and require orotracheal intubation throughout hospitalizationMeasure: Orotracheal Intubation Rate Time: 28 days
Description: number of patients who experienced adverse events after the immunoglobulin infusionMeasure: Infusional reaction rate Time: 28 days
Description: number of deceased patientsMeasure: Mortality rate Time: 28 days
Description: Frequency of adverse events classified following CTCAEMeasure: Assessment of adverse events Time: 28 days
Description: Results of a 7-point ordinal severity scaleMeasure: Evaluation of clinical status Time: Day 0, Day 14, Day 21 and Day 28
Description: Exploratory analysis of the variation of inflammatory markers by ELISA/Luminex and flow cytometry, compared to baseline levelsMeasure: Modulation of serum and cellular inflammatory marker Time: Day 0, Day 3 and Day 7.
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports